Email Updates

Search form

You are here


Oral tenofovir-based PrEP works. Faster, smarter rollout must be a top priority.

Recent clinical trials have shown clearly that daily, oral pre-exposure prophylaxis (PrEP) using the antiretroviral drugs tenofovir and emtricitabine dramatically reduces the risk of HIV infection for men and women who take it as directed. While PrEP won’t be right for every individual at risk for HIV, untold numbers of men and women will benefit—if they can access this potentially life-saving option.

So far, PrEP’s implementation has been piecemeal and incomplete. TDF/FTC is approved for use as oral PrEP in a handful of countries but, for maximum impact, PrEP rollout needs a coherent, global strategy involving many real-world demonstration projects, other research and guidance from global health agencies. At the same time, research into new PrEP formulations—such as intermittent use of pills or quarterly injections—could help improve adherence and achieve PrEP’s full potential.

What We're Reading

POZ has this detailed look at the history of PrEP since it became available in the US in 2012.

July 13, 2017

The FDA’s recent move to approve a generic Truvada comes with uncertainty and potential. This article, featured on, takes up the question of how the prevention field can and should prepare. Such preparations will necessarily be complex because the maker of the generic, TEVA Pharmaceuticals, and the maker of Truvada, Gilead, have penned an agreement making it secret exactly when the generic will be marketed.

July 6, 2017

The Vietnam Administration for AIDS Control launched an oral PrEP prescription service this past March. This pilot program will run until September 2018, when it will be re-evaluated by the Ministry of Health.

June 14, 2017
Viet Nam News
Subscribe to RSS - PrEP